Lipella Pharmaceuticals Inc is a biotechnology company organized around offering supportive care to cancer survivors who develop hemorrhagic cystitis, as well as improved surveillance and imaging of patients with a history of transitional cell carcinoma. Several of the firm's products are in clinical trials and available for licensing and/or co-development. Lipella maintains a manufacturing facility used for the development of liposomal formulations intended for intravesical delivery and for theproduction of the firm's clinical trial materials. Lipella also has in clinical-stage pharmaceutical assets in additional urinary bladder conditions, as well as urine-based diagnostics. In March 2019 the firm reported investigational new drug (IND) approval for a phase-2a, multi-center, double-blind, placebo-controlled clinical study measuring the safety and efficacy of LP-10 for cancer survivors with hemorrhagic cystitis resulting from pelvic radiation therapy and/or systemic chemotherapy.
